**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71466

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Diagnostic value of artificial intelligence automatic detection systems for breast BI-RADS 4 nodules**

Lyu SY *et al*. AI diagnose of BI-RADS 4 nodules

Shu-Yi Lyu, Yan Zhang, Mei-Wu Zhang, Bai-Song Zhang, Li-Bo Gao, Lang-Tao Bai, Jue Wang

**Shu-Yi Lyu, Yan Zhang, Mei-Wu Zhang, Bai-Song Zhang, Li-Bo Gao, Lang-Tao Bai,** Interventional Therapy Department, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, Zhejiang Province, China

**Shu-Yi Lyu, Yan Zhang, Mei-Wu Zhang, Bai-Song Zhang, Li-Bo Gao, Lang-Tao Bai,** Interventional Therapy Department, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315010, Zhejiang Province, China

**Jue Wang,** Ultrasonography Department, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, Zhejiang Province, China

**Jue Wang,** Ultrasonography Department, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315010, Zhejiang Province, China

**Author contributions:** Lyu SY designed and performed the research and wrote the paper; Zhang Y designed the research and supervised the report; Zhang MW and Zhang BS designed the research and contributed to the analysis; Gao LB and Bai LT collected data and contributed to the analysis; Wang J supervised the report.

**Supported by** Zhejiang Medical and Health Science and Technology Plan Project, No. 2020KY837 and No. 2020KY852.

**Corresponding author: Yan Zhang, MD, Chief Doctor,** Interventional Therapy Department, Hwa Mei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Ningbo 315010, Zhejiang Province, China. wjcclsy@163.com

**Received:** September 14, 2021

**Revised:** October 22, 2021

**Accepted:** November 29, 2021

**Published online:** January 14, 2022

**Abstract**

BACKGROUND

The incidence rate of breast cancer has exceeded that of lung cancer, and it has become the most malignant type of cancer in the world. BI-RADS 4 breast nodules have a wide range of malignant risks and are associated with challenging clinical decision-making.

AIM

To explore the diagnostic value of artificial intelligence (AI) automatic detection systems for BI-RADS 4 breast nodules and to assess whether conventional ultrasound BI-RADS classification with AI automatic detection systems can reduce the probability of BI-RADS 4 biopsy.

METHODS

A total of 107 BI-RADS breast nodules confirmed by pathology were selected between June 2019 and July 2020 at Hwa Mei Hospital, University of Chinese Academy of Sciences. These nodules were classified by ultrasound doctors and the AI-SONIC breast system. The diagnostic values of conventional ultrasound, the AI automatic detection system, conventional ultrasound combined with the AI automatic detection system and adjusted BI-RADS classification diagnosis were statistically analyzed.

RESULTS

Among the 107 breast nodules, 61 were benign (57.01%), and 46 were malignant (42.99%). The pathology results were considered the gold standard; furthermore, the sensitivity, specificity, accuracy, Youden index, and positive and negative predictive values were 84.78%, 67.21%, 74.77%, 0.5199, 66.10% and 85.42% for conventional ultrasound BI-RADS classification diagnosis, 86.96%, 75.41%, 80.37%, 0.6237, 72.73%, and 88.46% for automatic AI detection, 80.43%, 90.16%, 85.98%, 0.7059, 86.05%, and 85.94% for conventional ultrasound BI-RADS classification with automatic AI detection and 93.48%, 67.21%, 78.50%, 0.6069, 68.25%, and 93.18% for adjusted BI-RADS classification, respectively. The biopsy rate, cancer detection rate and malignancy risk were 100%, 42.99% and 0% and 67.29%, 61.11%, and 1.87% before and after BI-RADS adjustment, respectively.

CONCLUSION

Automatic AI detection has high accuracy in determining benign and malignant BI-RADS 4 breast nodules. Conventional ultrasound BI-RADS classification combined with AI automatic detection can reduce the biopsy rate of BI-RADS 4 breast nodules.

**Key Words:** BI-RADS classification; Artificial intelligence; Breast nodules; Breast tumor

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lyu SY, Zhang Y, Zhang MW, Zhang BS, Gao LB, Bai LT, Wang J. Diagnostic value of artificial intelligence automatic detection systems for breast BI-RADS 4 nodules. *World J Clin Cases* 2022; 10(2): 518-527

URL: https://www.wjgnet.com/2307-8960/full/v10/i2/518.htm

DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.518

**Core Tip:** The accuracy of the AI-SONIC breast system in diagnosing BI-RADS 4 nodules is very high, which can improve the diagnostic accuracy of young doctors. It can also be used to upgrade and downgrade BI-RADS 4 nodules, guide clinical decision-making, reduce the biopsy rate for BI-RADS 4 nodules and prevent the waste of medical resources.

**INTRODUCTION**

Breast cancer is the most common malignancy among women worldwide. It is also the leading cause of cancer death in women, seriously threatening health[1]. In January 2021, the American Cancer Society noted in their 2020 global cancer statistics report[2] that the incidence rate of breast cancer has exceeded that of lung cancer, and it has become the type of cancer with the greatest number of malignant tumors worldwide (accounting for 11.7% of the total number of new cases). In addition, the mortality rate of breast cancer (6.9%) ranks fifth among cancers. Ultrasound is an important imaging examination method for breast cancer screening. In 2013, the American Society of Radiology released the fifth edition of the BI-RADS, which added ultrasound content based on the fourth edition and promoted standardized examination of breast ultrasound[3]. However, the malignancy risk of BI-RADS class 4 nodules covers a wide range of 2%-95%, clinical decision-making is challenging, and further puncture biopsy or surgical treatment is often required[4]. Artificial intelligence (AI) automatic detection systems for ultrasound breast cancer screening have attracted the attention of scholars in recent years because of their advantages of rapidity, accuracy and objectivity, providing efficient and accurate support to determine the benign or malignant nature of breast nodules[5]. This study attempted to explore whether an AI automatic detection system helps distinguish benign and malignant BI-RADS 4 breast nodules to reduce the likelihood of biopsy.

**MATERIALS AND METHODS**

***Study design***

From June 2019 to July 2020, 107 breast nodules from 92 patients with BI-RADS class 4 nodules, which were detected by routine ultrasound examination in our hospital and confirmed by pathology through puncture biopsy or operation, were examined. The maximum diameter of the nodules was 0.5-3.7 cm. All the patients were women aged 22-83 (45.1 ± 13.2) years who had undergone routine ultrasound and AI automatic detection system examination before surgery. The exclusion criteria were as follows: patients under the age of 18; patients who were pregnant or lactating; patients with breast prosthesis implantation; or patients with a history of previous breast surgery. The study was approved by the ethics committee of our hospital (ethics approval No. pj-nbey-ky-2019-060-01). All the subjects signed informed consent before the examination.

***Ultrasound scanners and AI software***

The examination was performed by 2 ultrasound doctors with professional training and 2 years of breast examination experience using a commercially available unit, EPIQ7 (Philips), with a high-frequency linear array probe (5–12 MHz).

Demetics is an AI system based on the deep learning framework De-Light that utilizes ultrasound images for big data analysis of breast nodules. Two convolutional neural networks (CNNs) of large and small sizes were built into the system, and the nodule probability was calculated for each pixel. Then, the separated connected regions were cascaded into a new CNN for 2 classifications. The system has good learning ability and growth after in-depth learning of approximately 50000 breast nodule pathological results. This model automatically identifies two-dimensional grayscale ultrasound images of breast nodules. Radiologists do not need to outline breast nodules. The operator must only import ultrasound images into Demetics, and the system obtains the risk coefficient of the thyroid nodule. The range of the risk coefficient is 0-1, and the cutoff value is set to be 0.5 by the system. If the risk coefficient is ≥ 0.5, the nodule is diagnosed as malignant; if the risk coefficient is < 0.5, the nodule is diagnosed as benign.

***Study pipeline***

The patient was placed in the supine position, and the upper limbs were raised to fully expose the breast and armpit. Two ultrasound doctors who had received professional training and had 2 years of breast examination experience performed the procedure. After discovering the nodule, they carefully observed it, recorded the boundary, shape and internal echo of the nodule, and classified it according to the BI-RADS classification standard recommended by Zhou *et al*[6]. In cases of disagreement, the result was determined by negotiation. Irregular shape, vertical growth, boundary hyperechoic halo, irregular edge, microcalcification and posterior echo attenuation were considered malignant indices: if one index was satisfied, the lesion was classified as 4A; if two indices were satisfied, it was classified as 4B; if three indices were satisfied, it was classified as 4C; if four or more indices were satisfied, it was classified as 5. In this study, conventional ultrasound BI-RADS classification defined class 4A nodules as benign and class 4B and 4C nodules as malignant. BI-RADS 4 nodules were selected for detection by an AI automatic detection system.

After routine ultrasound examination, the two doctors used AI automatic detection systems (professional technicians performed AI pre-job training for operators in the early stage). Static ultrasound images that clearly showed breast nodules were transmitted in DICOM format in real time and stored in an automatic sonic breast detection system for automatic labeling, processing and analysis. The breast nodules were automatically quantified and identified through the AI algorithm. According to the malignant characteristics of BI-RADS of the American College of Radiology[4], breast nodules include edge features, structural features, and calcification. The five characteristics of echo type and growth direction can be used to automatically assess benign and malignant nodules, and the probability value of benign and malignant nodules is interpreted by the recording system.

For conventional ultrasound BI-RADS classification with the AI automatic detection system prediction model, malignancy was considered when both indicated malignancies; otherwise, the diagnosis was benign. The prediction model of the AI automatic detection system adjusts the classification of conventional ultrasonic BI-RADS: if the AI score is greater than 0.5, the classification is increased by one category; if the AI score is less than 0.5, the classification is decreased by one category[7].

***Statistical analysis***

SPSS 21.0 statistical analysis software was used to calculate the sensitivity, specificity, accuracy, Jordan index, positive predictive value and negative predictive value of the conventional ultrasound BI-RADS classification, AI automatic detection system, conventional ultrasound BI-RADS classification with AI automatic detection system and adjusted BI-RADS classification diagnosis; the pathological results were used as the gold standard. The biopsy rate, cancer detection rate and malignancy risk rate of post BI-RADS classification diagnosis were compared with the *χ*2 test. In all analyses, a *P* value below 0.05 was considered significant.

**RESULTS**

***Pathological results***

Among the 107 breast nodules, 61 were benign (57.01%), namely, 32 cases of fibroadenoma, 18 of adenopathy, 3 of granulomatous mastitis, 2 of intraductal papilloma, 2 of galactocele, 1 of plasma cell mastitis, 1 of phyllodes tumor, 1 of sclerosing adenosis, and 1 of nodular fasciitis, and 46 were malignant (42.99%), including 31 invasive ductal carcinomas. There were 5 cases of intraductal papillary carcinoma, 4 of invasive lobular carcinoma, 2 of encapsulated papillary carcinoma, 1 of mucinous carcinoma, 1 of undifferentiated carcinoma, 1 of malignant phyllodes tumor and 1 of solid papillary carcinoma (Table 1).

***Comparison of the four diagnostic models with pathological results***

According to conventional ultrasound BI-RADS classification, 4A nodules were classified as benign, and 4B and 4C nodules were classified as malignant; therefore, 59 malignant and 48 benign nodules were diagnosed. The AI automatic detection system defined 0-0.5 as benign and 0.6-1 as malignant, and 55 malignant and 52 benign nodules were diagnosed (Figure 1 and Figure 2). For conventional ultrasound BI-RADS classification with an AI automatic detection system, the presence of malignancy indices was defined as malignant, and others were defined as benign; therefore, 43 malignant and 64 benign nodules were diagnosed. According to the adjusted BI-RADS classification, if the AI score was greater than 0.5, the classification was upgraded by one category, and if the AI score was less than 0.5, the classification was downgraded by one category; therefore, 63 malignant and 44 benign nodules were diagnosed. BI-RADS classification distribution and risk prediction before and after adjustment were also performed (Table 2).

***Diagnostic efficiency of the four diagnostic models***

The pathology results were considered the gold standard; furthermore, the sensitivity, specificity, accuracy, Youden index, positive predictive value and negative predictive value of conventional ultrasound BI-RADS classification diagnosis, the AI automatic detection system, the conventional ultrasound BI-RADS classification combined with AI automatic detection system and adjusted BI-RADS classification diagnosis were 84.78%, 67.21%, 74.77%, 0.5199, 66.10% and 85.42%; 86.96%, 75.41%, 80.37%, 0.6237, 72.73%, and 88.46%; 80.43%, 90.16%, 85.98%, 0.7059, 86.05%, and 85.94%; and 93.48%, 67.21%, 78.50%, 0.6069, 68.25%, and 93.18%, respectively (Table 3).

**DISCUSSION**

The incidence and mortality of breast cancer in China are increasing annually with a growing disease burden. The prevention and treatment of breast cancer are very important[8]. Indeed, early accurate, reliable diagnosis and treatment are crucial for patient prognosis[9,10]. With the screening of breast cancer and attention to health, an increasing number of asymptomatic breast nodules are being identified[11]. According to the National Comprehensive Cancer Network breast cancer clinical practice guidelines[12], BI-RADS 4-type breast nodules should be assessed by biopsy, but only 2% of all breast nodules are positive. Chaiwerawattana *et al*[13] have reported that 92.35% of patients with BI-RADS class 4 breast nodules screened by the guidelines underwent unnecessary biopsies. This issue creates a burden on patients and wastes many medical resources. Although breast ultrasound has the advantages of simple operation, no radiation and low cost, it has large operator dependence and poor repeatability. In fact, there are great differences in ultrasound execution and the interpretation of images, which results in different BI-RADS classifications. For example, Wang *et al*[14] reported that among 220 cases of breast nodules, BI-RADS 4A was the dividing point between benign and malignant lesions. After multiple ultrasound examinations, up to 21.8% of cases had two different diagnostic results, which creates confusion among clinicians. This study aimed to find an objective and noninvasive method to determine benign and malignant BI-RADS class 4 nodules by applying an AI automatic detection system.

AI has powerful image analysis and information processing capabilities[15,16] and can mine ultrasonic image information that cannot be captured by human eyes. It can quickly, accurately and objectively analyze images, reduce doctors' burden, alleviate the impact on medical resources, improve the accuracy of diagnosis and help clinicians in prognosis and risk stratification to benefit a majority of patients[17,18]. The AI-SONIC Breast classification technology uses BI-RADS classification as the diagnosis basis, integrates scanning, reading and reporting, and can provide a comprehensive and objective evaluation. The AI-SONIC Breast system has high diagnostic efficiency. In this study, the AI automatic detection systems had higher sensitivity, specificity and accuracy than young doctors but lower diagnostic efficiency than the ultrasonic s-detect classification technology for breast nodules reported by Zhou *et al*[19]. The reason may be that different AI systems have different degrees of machine training. The nodules selected in this study were BI-RADS 4 and above, excluding some simple and typical benign lesions and increasing the difficulty of diagnosis. The accuracy of the AI-SONIC Breast system with conventional ultrasound BI-RADS classification was 85.98%, which is significantly higher than that of the conventional ultrasound BI-RADS classification (74.77%) and indicates that AI automatic detection has high diagnostic efficiency for BI-RADS class 4 breast nodules, *e.g.*, higher than that of young doctors. Its application in the clinic can improve the diagnostic accuracy of young doctors and increase diagnostic confidence. The system can also be used to upgrade and downgrade BI-RADS class 4 nodules and guide decision-making. The adjusted BI-RADS classification decreased the biopsy rate of breast nodules from 100% to 67.29%, which greatly reduced unnecessary puncture biopsy. The cancer detection rate of BI-RADS classification after adjustment was approximately 61.11%, which was significantly higher than that before adjustment (42.99%); this will help to effectively avoid the waste of medical resources. According to the adjusted BI-RADS classification, the risk of malignancy was approximately 1.87%, and only 2 cases of malignant nodules were downgraded to class 3. One case was mucinous carcinoma, and both conventional ultrasound BI-RADS classification and the AI detection system classified this nodule as benign, *i.e.*, a missed diagnosis. The reason is that breast mucinous carcinoma is a special type of malignant breast tumor with a low incidence rate and is often neglected[20], and its growth is inflated. Sonograms of breast mucinous carcinoma mostly reveal hypoechoic nodules with clear borders and regular morphology, and the posterior echo is enhanced. In general, there is no calcification and no obvious blood flow signal. It has similar sonographic features to benign breast tumors, which are easily misdiagnosed as breast fibroadenoma or adenosis[21]. In our study, this nodule was diagnosed as a BI-RADS 4A nodule by conventional ultrasound. The score of the AI detection system was 0.44, which indicated benign. The other case involved intraductal papillary carcinoma; the nodule was small, and the maximum diameter was only 4 mm. Conventional ultrasound showed that the nodule grew nearly vertically, which was consistent with malignancy, and it was diagnosed as a BI-RADS 4A nodule. The AI detection system suggested 0.38, which was benign. In such cases, a missed diagnosis (or misdiagnosis) can be corrected, and a diagnosis and treatment plan can be decided through short-term follow-up or combined with other new technologies, such as breast contrast-enhanced ultrasound[22], ultrasonic elastography[23], automatic breast volume scanner[24] or puncture biopsy.

The limitations of this article are as follows: (1) the sample size was small, the pathological types were incomplete, and there were no special types of breast cancer, such as neuroendocrine carcinoma, medullary carcinoma and Paget’s disease; (2) Conventional ultrasound was performed by two young doctors, and the diagnostic efficacy of different seniority doctors and AI automatic detection systems was not compared; and (3) the AI-SONIC breast system has certain limitations and cannot recognize and determine dynamic ultrasound images. Its feature analysis does not include important information such as the blood flow signal, peripheral echo and elastic characteristics, and there is a certain error in the judgment of equal echo or small nodules.

**CONCLUSION**

AI automatic detection has high accuracy in determining benign and malignant BI-RADS 4 breast nodules. Conventional ultrasound BI-RADS classification with AI automatic detection can reduce the biopsy rate of BI-RADS 4 breast nodules.

**ARTICLE HIGHLIGHTS**

***Research background***

With the popularization of breast screening, an increasing number of BI-RADS 4 nodules have been detected. According to clinical guidelines, such nodules require biopsy. However, the vast majority of BI-RADS 4 nodules are benign, which results in a large number of unnecessary biopsies.

***Research motivation***

To reduce the biopsy rate for BI-RADS 4 nodules and prevent the waste of medical resources.

***Research objectives***

Our goal is to improve the preoperative diagnostic accuracy of breast nodules as much as possible, not only to reduce misdiagnosis and missed diagnosis, but also to avoid unnecessary biopsy.

***Research methods***

We used an artificial intelligence (AI) system to regrade BI-RADS 4 nodules and used pathology results as the gold standard.

***Research results***

The diagnostic value of AI detection system is higher than that of other methods. The BI-RADS classification results adjusted by AI detection system are closer to the pathological results.

***Research conclusions***

The AI system has very high diagnostic efficiency for BI-RADS 4 nodules and can effectively prevent many unnecessary puncture biopsies of such nodules.

***Research perspectives***

In the future, we will continue to study the application of AI in breast cancer and use AI to predict the prognosis of breast cancer.

**REFERENCES**

1 **Ferlay J**, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]

2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

3 **Sprague BL**, Kerlikowske K, Bowles EJA, Rauscher GH, Lee CI, Tosteson ANA, Miglioretti DL. Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium. *J Natl Cancer Inst* 2019; **111**: 629-632 [PMID: 30624682 DOI: 10.1093/jnci/djy210]

4 **Mercado CL**. BI-RADS update. *Radiol Clin North Am* 2014; **52**: 481-487 [PMID: 24792650 DOI: 10.1016/j.rcl.2014.02.008]

5 **Kim K**, Song MK, Kim EK, Yoon JH. Clinical application of S-Detect to breast masses on ultrasonography: a study evaluating the diagnostic performance and agreement with a dedicated breast radiologist. *Ultrasonography* 2017; **36**: 3-9 [PMID: 27184656 DOI: 10.14366/usg.16012]

6 **Zhou JY**, Shen L, Zhan WW. Consistency and clinical significance of ultrasonic BI-RADS descriptors for breast masses. *Zhongguo Yixue Yingxiang Xue Zazhi* 2013; **21**: 672-674, 678 [DOI: 10.3969/j.issn.1005-5185.2013.09.011]

7 **Mai W**, Zhou M, Li J, Yi W, Li S, Hu Y, Ji J, Zeng W, Gao B, Liu H. The value of the Demetics ultrasound-assisted diagnosis system in the differential diagnosis of benign from malignant thyroid nodules and analysis of the influencing factors. *Eur Radiol* 2021; **31**: 7936-7944 [PMID: 33856523 DOI: 10.1007/s00330-021-07884-z]

8 **Lei S**, Zheng R, Zhang S, Chen R, Wang S, Sun K, Zeng H, Wei W, He J. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. *Cancer Biol Med* 2021 [PMID: 34002584 DOI: 10.20892/j.issn.2095-3941.2020.0523]

9 **Wang Y**, Fan W, Zhao S, Zhang K, Zhang L, Zhang P, Ma R. Qualitative, quantitative and combination score systems in differential diagnosis of breast lesions by contrast-enhanced ultrasound. *Eur J Radiol* 2016; **85**: 48-54 [PMID: 26724648 DOI: 10.1016/j.ejrad.2015.10.017]

10 **Sellami L**, Ben Sassi O, Chtourou K, Ben Hamida A. Breast Cancer Ultrasound Images' Sequence Exploration Using BI-RADS Features' Extraction: Towards an Advanced Clinical Aided Tool for Precise Lesion Characterization. *IEEE Trans Nanobioscience* 2015; **14**: 740-745 [PMID: 26513796 DOI: 10.1109/TNB.2015.2486621]

11 **Cao M**, Li H, Sun D, He S, Yu Y, Li J, Chen H, Shi J, Ren J, Li N, Chen W. Cancer screening in China: The current status, challenges, and suggestions. *Cancer Lett* 2021; **506**: 120-127 [PMID: 33684533 DOI: 10.1016/j.canlet.2021.02.017]

12 **Gradishar WJ**, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018; **16**: 310-320 [PMID: 29523670 DOI: 10.6004/jnccn.2018.0012]

13 **Chaiwerawattana A**, Thanasitthichai S, Boonlikit S, Apiwanich C, Worawattanakul S, Intakawin A, Rakiad S, Thongkham K. Clinical outcome of breast cancer BI-RADS 4 lesions during 2003-2008 in the National Cancer Institute Thailand. *Asian Pac J Cancer Prev* 2012; **13**: 4063-4066 [PMID: 23098517 DOI: 10.7314/apjcp.2012.13.8.4063]

14 **Wang XY**, Wei Q, Cui XW, Wang LP. Diagnostic value of S-Detect technology in differential diagnosis of breast cancer. *Zhonghua Chaosheng Yingxiangxue Zazhi* 2019; **28**: 246-250 [DOI: 10.3760/cma.j.issn.1004-4477.2019.03.011]

15 **Quon JL**, Chen LC, Kim L, Grant GA, Edwards MSB, Cheshier SH, Yeom KW. Deep Learning for Automated Delineation of Pediatric Cerebral Arteries on Pre-operative Brain Magnetic Resonance Imaging. *Front Surg* 2020; **7**: 517375 [PMID: 33195383 DOI: 10.3389/fsurg.2020.517375]

16 **Klimont M**, Oronowicz-Jaśkowiak A, Flieger M, Rzeszutek J, Juszkat R, Jończyk-Potoczna K. Deep learning for cerebral angiography segmentation from non-contrast computed tomography. *PLoS One* 2020; **15**: e0237092 [PMID: 32735633 DOI: 10.1371/journal.pone.0237092]

17 **Ho KC**, Speier W, El-Saden S, Arnold CW. Classifying Acute Ischemic Stroke Onset Time using Deep Imaging Features. *AMIA Annu Symp Proc* 2017; **2017**: 892-901 [PMID: 29854156]

18 **Dehkharghani S**, Lansberg M, Venkatsubramanian C, Cereda C, Lima F, Coelho H, Rocha F, Qureshi A, Haerian H, Mont'Alverne F, Copeland K, Heit J. High-Performance Automated Anterior Circulation CT Angiographic Clot Detection in Acute Stroke: A Multireader Comparison. *Radiology* 2021; **298**: 665-670 [PMID: 33434110 DOI: 10.1148/radiol.2021202734]

19 **Zhou YG,** Yuan LJ, Xing CY, Zhang L, Zhang YJ, Yang HL, Jing JL. Application value of ultrasonic S-Detect classification technique in the diagnosis of benign and malignant breast masses. *Zhonghua Chaosheng Yingxiangxue Zazhi* 2017; **26**: 1053-1056 [DOI: 10.3760/cma.j.issn.1004-4477.2017.12.009]

20 **Ranade A**, Batra R, Sandhu G, Chitale RA, Balderacchi J. Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. *J Clin Pathol* 2010; **63**: 1043-1047 [PMID: 20962055 DOI: 10.1136/jcp.2010.082495]

21 **Tan JZ**, Waugh J, Kumar B, Evans J. Mucinous carcinomas of the breast: imaging features and potential for misdiagnosis. *J Med Imaging Radiat Oncol* 2013; **57**: 25-31 [PMID: 23374550 DOI: 10.1111/1754-9485.12006]

22 **Luo J**, Chen JD, Chen Q, Yue LX, Zhou G, Lan C, Li Y, Wu CH, Lu JQ. Contrast-enhanced ultrasound improved performance of breast imaging reporting and data system evaluation of critical breast lesions. *World J Radiol* 2016; **8**: 610-617 [PMID: 27358689 DOI: 10.4329/wjr.v8.i6.610]

23 **Chang JM**, Moon WK, Cho N, Yi A, Koo HR, Han W, Noh DY, Moon HG, Kim SJ. Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. *Breast Cancer Res Treat* 2011; **129**: 89-97 [PMID: 21681447 DOI: 10.1007/s10549-011-1627-7]

24 **Li Y**, Wu W, Chen H, Cheng L, Wang S. 3D tumor detection in automated breast ultrasound using deep convolutional neural network. *Med Phys* 2020; **47**: 5669-5680 [PMID: 32970838 DOI: 10.1002/mp.14477]

**Footnotes**

**Institutional review board statement:** The study was approved by the ethics committee of Hwa Mei Hospital, University of Chinese Academy of Sciences (Approval No. pj-nbey-ky-2019-060-01).

**Informed consent statement:** All the subjects signed informed consent before the examination.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**Data sharing statement:** Except the data in the text, no other data can be provided.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 14, 2021

**First decision:** October 18, 2021

**Article in press:** November 29, 2021

**Specialty type:** Radiology, Nuclear Medicine and Medical Imaging

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Campos-da-Paz M, Prat A **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Wang JL

**Figure Legends**



**Figure 1 AI-SONIC breast system automatically recognizes markers and quantifies breast nodule characteristics.** BI-RADS 4C, breast invasive ductal carcinoma confirmed by pathological findings. A: Conventional ultrasound BI-RADS classification suggests BI-RADS 4C; B: Automatic measurement and display of the growth direction; C: Edge feature analysis: the color changes from blue, green, yellow and red in turn to clear to blur; D: The dotted red line represents a strong echo; E: Based on the longitudinal section of the right breast nodule, the benign and. malignancy probability of this lesion was 0.84, as detected by artificial intelligence; F: The pathological diagnosis was invasive ductal carcinoma of the breast.



**Figure 2 AI-SONIC breast system automatically recognizes markers and quantifies breast nodule characteristics.** BI-RADS 4A, breast fibroadenoma confirmed by pathological findings. A: Conventional ultrasound BI-RADS classification suggests BI-RADS 4A; B: Automatic measurement and display of the growth direction; C: Edge feature analysis: the color changes from blue, green, yellow and red in turn to clear to blur; D: The dotted red line represents a strong echo; E: Based on the longitudinal section of the right breast nodule, the benign and malignancy probability of this lesion was 0.39, as detected by artificial intelligence; F: The pathological diagnosis was fibroadenoma of the breast.

**Table 1 results of 107 breast cases**

|  |  |
| --- | --- |
| **Pathological results** | **Number of nodules** |
| Benign |  |
| Fibroadenoma | 32 |
| Adenosis | 18 |
| Granulomatous mastitis | 3 |
| Intraductal papilloma | 2 |
| Galactocele | 2 |
| Plasma cell mastitis | 1 |
| Phyllodes tumor | 1 |
| Sclerosing adenosis | 1 |
| Nodular fasciitis | 1 |
| Malignant |  |
| Invasive ductal carcinoma | 31 |
| Intraductal papillary carcinoma | 5 |
| Invasive lobular carcinoma | 4 |
| Encapsulated papillary carcinoma | 2 |
| Mucinous carcinoma | 1 |
| Undifferentiated carcinoma | 1 |
| Malignant phyllodes tumor | 1 |
| Solid papillary carcinoma | 1 |

**Table 2 Diagnostic efficiency of four diagnostic models**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Inspection method** | **Pathology** | | **Susceptibility (%)** | **Specificity (%)** | **Accuracy (%)** | **Jordan index** | **Positive predictive value (%)** | **Negative predictive value (%)** |
| **Benign (*n* = 61)** | **Malignant (*n* = 46)** |
| Conventional ultrasound BI-RADS classification |  |  | 84.78 | 57.21 | 74.44 | 0.5199 | 61.11 | 85.42 |
| Benign (*n* = 48) | 41 | 7 |  |  |  |  |  |  |
| Malignant (*n* = 59) | 20 | 39 |  |  |  |  |  |  |
| AI-SONIC Breast system |  |  | 86.96 | 75.41 | 80.37 | 0.6237 | 72.73 | 88.46 |
| Benign (*n* = 52) | 46 | 6 |  |  |  |  |  |  |
| Malignant (*n* = 53) | 15 | 40 |  |  |  |  |  |  |
| AI-SONIC Breast system combined BI-RADS classification of conventional ultrasound |  |  | 80.43 | 90.16 | 85.98 | 0.7059 | 86.05 | 85.94 |
| Benign (*n* = 64) | 55 | 9 |  |  |  |  |  |  |
| Malignant (*n* = 43) | 6 | 37 |  |  |  |  |  |  |
| Adjusted BI-RADS classification |  |  | 93.48 | 67.21 | 78.50 | 0.6069 | 68.25 | 93.18 |
| Benign (*n* = 44) | 41 | 3 |  |  |  |  |  |  |
| Malignant (*n* = 63) | 20 | 43 |  |  |  |  |  |  |

**Table 3 BI-RADS classification distribution and risk prediction before and after adjustment**

|  |  |  |  |
| --- | --- | --- | --- |
| **Inspection method** | **Biopsy rate (%)** | **Malignancy risk (%)** | **Cancer detection rate (%)** |
| BI-RADS classification before adjustment | 100 | 0 | 42.99 |
| 4A (*n* = 48) |  |  |  |
| 4B (*n* = 20) |  |  |  |
| 4C (*n* = 39) |  |  |  |
| Adjusted BI-RADS classification | 67.29 | 1.87 | 61.11 |
| 3 (*n* = 35) |  |  |  |
| 4A (*n* = 9) |  |  |  |
| 4B (*n* = 20) |  |  |  |
| 4C (*n* = 11) |  |  |  |
| 5 (*n* = 32) |  |  |  |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**